FIELD: biotechnology.
SUBSTANCE: following are presented: an antibody or its antigen-binding fragment that binds to TIE-2 tyrosine-protein kinase receptor and a method for their production, a nucleic acid encoding an antibody or its antigen-binding fragment, an expression vector, a cell transformed with an expression vector to obtain an antibody or its antigen-binding fragment. Also a composition is provided for preventing or treating an angiogenesis-related disease, a composition for stabilizing blood vessels, a composition for diagnosing an angiogenesis-related disease, a composition for preventing or treating cancer, a composition for preventing or treating a tumor, and the use of a composition containing a pharmaceutically effective the amount of the antibody or antigen-binding fragment thereof.
EFFECT: invention makes it possible to obtain an antibody or its antigen-binding fragment that binds to TIE-2 tyrosine-protein kinase receptor, as well as compositions for the prevention or treatment of an angiogenesis-related disease.
16 cl, 18 dwg, 4 tbl, 13 ex
Title | Year | Author | Number |
---|---|---|---|
PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
ANTIBODY AGAINST ANG2 AND ITS USE | 2020 |
|
RU2788088C1 |
ANTIBODIES AGAINST VISTA AND APPLICATION THEREOF | 2018 |
|
RU2750723C1 |
ANTIBODIES AGAINST LIGAND-1 PROGRAMMED DEATH (PD-L1) AND APPLICATION THEREOF | 2017 |
|
RU2721582C1 |
ANTIBODIES TO HUMAN INTERLEUKIN-2 AND THEIR APPLICATION | 2018 |
|
RU2745451C1 |
ANTI-DR5 ANTIBODY AND USE THEREOF | 2018 |
|
RU2735956C1 |
ANTIBODIES AGAINST A5 REPRESENTATIVE OF 19 FAMILY WITH SIMILARITY OF SEQUENCES AND THEIR APPLICATION METHOD | 2019 |
|
RU2785436C2 |
ANTIBODY AGENTS SPECIFIC TO HUMAN CD19, AND THEIR APPLICATIONS | 2016 |
|
RU2773317C2 |
COMPOSITION FOR PREVENTION AND TREATMENT OF SKIN DISEASE CONTAINING SUBSTANCE SPECIFICALLY BINDING WITH VIMENTINE DERIVATIVE PEPTIDE | 2018 |
|
RU2751486C1 |
NEW MONOCLONAL ANTIBODIES TO PROGRAMMED CELL DEATH 1 (PD-1) PROTEIN | 2016 |
|
RU2757316C2 |
Authors
Dates
2023-05-03—Published
2020-08-14—Filed